Alpine Global Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Alpine Global Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,306	Closed	-$1.29M	–	287
2020 Q3	$1.29M	Buy	+2,306	New	+$1.4M	0.27%	55
2020 Q1	–	Sell	-1,334	Closed	-$501K	–	400
2019 Q4	$501K	Buy	+1,334	New	+$449K	0.11%	160
2017 Q4	–	Sell	-734	Closed	-$328K	–	263
2017 Q3	$328K	Buy	+734	New	+$349K	0.09%	136
2015 Q3	–	Sell	-344	Closed	-$175K	–	658
2015 Q2	$175K	Buy	+344	New	+$168K	0.03%	433
2015 Q1	–	Sell	-1,546	Closed	-$634K	–	469
2014 Q4	$634K	Buy	+1,546	New	+$608K	0.11%	201

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Alpine Global Management's REGN Position: Q4 2020 in Review

Alpine Global Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2020, closing a stake of 2,306 shares — an estimated $1.29M sold.

Alpine Global Management first reported a position in REGN in Q4 2014 and held it in 5 quarters. The position peaked at $1.29M in Q3 2020. 904 funds tracked by Wall St. Rank hold REGN as of Q4 2020.

Alpine Global Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Alpine Global Management sold 2,306 Regeneron Pharmaceuticals shares in Q4 2020, an estimated $1.29M.
Alpine Global Management first reported a position in Regeneron Pharmaceuticals in Q4 2014 and held it in 5 quarters.
Alpine Global Management's Regeneron Pharmaceuticals position peaked at $1.29M in Q3 2020.
904 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2020.

Based on Alpine Global Management's 13F filing for Q4 2020, filed 12 Feb 2021.